JP2022540611A5 - - Google Patents

Info

Publication number
JP2022540611A5
JP2022540611A5 JP2022501134A JP2022501134A JP2022540611A5 JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5 JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022501134A
Other languages
English (en)
Japanese (ja)
Other versions
JP7661299B2 (ja
JP2022540611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/041282 external-priority patent/WO2021007371A1/en
Publication of JP2022540611A publication Critical patent/JP2022540611A/ja
Publication of JP2022540611A5 publication Critical patent/JP2022540611A5/ja
Priority to JP2025061352A priority Critical patent/JP2025156278A/ja
Application granted granted Critical
Publication of JP7661299B2 publication Critical patent/JP7661299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022501134A 2019-07-11 2020-07-08 Dll3をターゲッティングする抗体とその使用 Active JP7661299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025061352A JP2025156278A (ja) 2019-07-11 2025-04-02 Dll3をターゲッティングする抗体とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962872915P 2019-07-11 2019-07-11
US62/872,915 2019-07-11
PCT/US2020/041282 WO2021007371A1 (en) 2019-07-11 2020-07-08 Dll3-targeting antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025061352A Division JP2025156278A (ja) 2019-07-11 2025-04-02 Dll3をターゲッティングする抗体とその使用

Publications (3)

Publication Number Publication Date
JP2022540611A JP2022540611A (ja) 2022-09-16
JP2022540611A5 true JP2022540611A5 (cg-RX-API-DMAC7.html) 2023-07-12
JP7661299B2 JP7661299B2 (ja) 2025-04-14

Family

ID=74115317

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022501134A Active JP7661299B2 (ja) 2019-07-11 2020-07-08 Dll3をターゲッティングする抗体とその使用
JP2025061352A Pending JP2025156278A (ja) 2019-07-11 2025-04-02 Dll3をターゲッティングする抗体とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025061352A Pending JP2025156278A (ja) 2019-07-11 2025-04-02 Dll3をターゲッティングする抗体とその使用

Country Status (13)

Country Link
US (1) US12441789B2 (cg-RX-API-DMAC7.html)
EP (1) EP3997127A4 (cg-RX-API-DMAC7.html)
JP (2) JP7661299B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220034167A (cg-RX-API-DMAC7.html)
CN (3) CN119080930A (cg-RX-API-DMAC7.html)
AU (1) AU2020310894A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000216A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146566A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001195A2 (cg-RX-API-DMAC7.html)
IL (1) IL289585A (cg-RX-API-DMAC7.html)
MX (1) MX2022000325A (cg-RX-API-DMAC7.html)
PH (1) PH12022550056A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021007371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2718257T3 (cg-RX-API-DMAC7.html) * 2014-05-30 2018-04-14
US12441789B2 (en) * 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof
EP4277665A1 (en) * 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
CN117425501A (zh) * 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
US20240239878A1 (en) * 2021-05-08 2024-07-18 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Binding molecule against dll3 and use thereof
CA3230627A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Antigen recognizing receptors targeting dll3 and uses thereof
WO2023034557A1 (en) * 2021-09-02 2023-03-09 Memorial Sloan-Kettering Cancer Center Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗dll3抗体及びその使用
TW202346346A (zh) * 2021-12-23 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 抗dll3抗體、其抗體-藥物偶聯物及其醫藥用途
IL314678A (en) 2022-02-27 2024-10-01 Boehringer Ingelheim Int Bispecific antibodies against cd277 and a tumor-antigen
CN116003628B (zh) * 2022-08-15 2026-08-04 南京博安生物技术有限公司 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用
WO2025184421A1 (en) * 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
EP2094307A4 (en) * 2006-11-08 2015-08-26 Macrogenics West Inc TES7 AND THEREO BINDING ANTIBODIES
PL2530091T3 (pl) 2010-01-29 2018-08-31 Chugai Seiyaku Kabushiki Kaisha Przeciwciało przeciwko dll3
EP2598532B1 (en) 2010-07-30 2017-07-12 Gianluca Moroncini Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof
ES2886123T3 (es) * 2012-01-31 2021-12-16 Regeneron Pharma Anticuerpos anti-asic1 y usos de los mismos
CN104520324A (zh) * 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
EP3107576A4 (en) * 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
RS61010B1 (sr) * 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
US12441789B2 (en) * 2019-07-11 2025-10-14 Memorial Sloan Kettering Cancer Center DLL3-targeting antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP7235256B2 (ja) 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途
CN105579471B (zh) 结合人程序性死亡配体1(pd-l1)的抗体
JP7624497B2 (ja) ヒトpd-l2抗体およびその使用方法
JP2009100745A5 (cg-RX-API-DMAC7.html)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
US12325747B2 (en) Human PD-L1 antibodies and methods of use therefor
JP2005518789A5 (cg-RX-API-DMAC7.html)
JP7713995B2 (ja) ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法
JP2024506315A5 (cg-RX-API-DMAC7.html)
JP2022538117A5 (cg-RX-API-DMAC7.html)
JP2023537002A5 (cg-RX-API-DMAC7.html)
US20250129167A1 (en) Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
JP2024540148A5 (cg-RX-API-DMAC7.html)
CN112979795A (zh) 抗体组合产品及其在新冠肺炎检测中应用
RU2021139258A (ru) Dll3-нацеливающие антитела и их применения
CN118240079A (zh) 抗脂联素抗体、检测脂联素的试剂和试剂盒
CN120424221B (zh) 靶向德曲妥珠单抗的抗体及其用途
TW201915016A (zh) 單株抗體或其抗原結合片段及其用途
JP2025512888A (ja) ヒトpd-l1およびpd-l2に対する二重特異性抗体ならびにその使用方法
CN121975014A (zh) 抗dll3的抗体及其相关产品和应用
KR20250064725A (ko) 사스 코로나바이러스 2 중화를 위한 이뮤노글로불린 a 항체 및 이의 용도
JP2024531913A5 (cg-RX-API-DMAC7.html)